{"name":"Kymera Therapeutics","slug":"kymera","ticker":"KYMR","exchange":"NASDAQ","domain":"kymeratx.com","description":"Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of d","hq":"Cambridge, MA","founded":0,"employees":"238","ceo":"Nello Maine","sector":"Immunology / Protein Degradation","stockPrice":86.56,"stockChange":1.46,"stockChangePercent":1.72,"marketCap":"$7.1B","metrics":{"revenue":60000000,"revenueGrowth":-61.2,"grossMargin":0,"rdSpend":0,"netIncome":-311351008,"cash":848275968,"dividendYield":0,"peRatio":-21.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"KT-333 patent cliff ($0.0B at risk)","drug":"KT-333","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Kymera Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Kymera Therapeutics reported its fourth quarter and full year 2023 financial results, which included a net loss of $44.6 million and a cash balance of $343.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Kymera Therapeutics Announces Collaboration with Merck to Develop Small Molecule Degraders","summary":"Kymera Therapeutics announced a collaboration with Merck to develop small molecule degraders for the treatment of various diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPVFJEcTN3OXc3WXZEZE9WazhqbndaOE1nUmFKMTJ2cGRVeGRJVFh4NjVUaXI3WmlwUnhtYUNuT2VlbG04cVYwcE1QcWRtSjgtV1poMWNxczY3OTlBR0xZVExWVHVsV2ltTWdIRDczWmVoNVREVF96cnZKRjc5ekFPQUtZODhIQWc2blBGUVBzbWdzY0hFX3BvNHZwSlNnbEVZSnNTd3RBSEYwTG9ISlNyeFg3RGU5d0RuRG9CdmREeEVrTXpyYldILU9BUmo1MEZBMHJvNEtvS05wSHpuV19idnZxQ1pvLXfSAewBQVVfeXFMUHRaVFpvbXprZU9SWEI0eElXd1hubkdSbF8xZzZ5ZGhtVUcyS0RRODFQR2NHYUVnYmYyQUhpZEM4Tk90LUFrcTMtNjg0MUxldV9KV0VpWjBDc284ZDg3Ym4zTmstSlVVc2Q2RFhOeW9seWtMcksyZGZSb2FRTjVvc1RCOHVIZkhtdEFTdXdFVzM3MDg0QjBxRFdaZEkyTzZERDBORGdyT0Nxa3ppWjJCaUl5cktzVWsyekFqZlF0ZjNrQ3JwdG80djc0Wl9BVkY5Y2ZDNDhOcWtDaWpEZ2hXbXhhWDcyOUQ2X01RSEo?oc=5","date":"2026-04-05","type":"trial","source":"simplywall.st","summary":"A Look At Kymera Therapeutics (KYMR) Valuation After Positive KT-621 Atopic Dermatitis Data - simplywall.st","headline":"A Look At Kymera Therapeutics (KYMR) Valuation After Positive KT-621 Atopic Dermatitis Data","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOdDU4bTd0VHE1VWlQYmlucWVJd3RxT0lucHQta0t3UjZRRlJkS2tlV0lqaGVqdTFpQko1cGNDdlZSak5qd1U0b21VdXRXRnlPLVJDanppR2VsVFpuZGhTVm5HSzZFaUpBaVRDN1NBSnpKdDl5cDFNdDhQTlNZSDlRQ3BTdHl1Y3pTRXRrcmJEdUlVQjEwd2hGQi1fbHhNR2dLZEthaURRdmxsX1h2?oc=5","date":"2026-04-01","type":"pipeline","source":"24/7 Wall St.","summary":"5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - 24/7 Wall St.","headline":"5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-29","type":"trial","source":"simplywall.st","summary":"How Investors Are Reacting To Kymera Therapeutics (KYMR) Oral STAT6 Degrader’s Positive Phase 1b Atopic Dermatitis Data - simplywall.st","headline":"How Investors Are Reacting To Kymera Therapeutics (KYMR) Oral STAT6 Degrader’s Positive Phase 1b Atopic Dermatitis Data","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOcWtiZWttamdqMHREaTlMbWprYWxUa1k0XzdkTTU4NHY5dmQyQUhyTXJQTmxPMEp4TV9ELWpVUUxvZnVITkRRdTVVVjRzUGtTOUoyMm91aGVOZ2h5bENLSlhHY1RhWHdibzlkV3hBaThyX3R4bG1FeXpZTXNKemc2YUhRVXh4YXgwbE9SRnA5NTNINU5mbDlyVEhtcDAyNTBIcGhOTEs3SzROdDZ6V0Y5OWtpTHdBcExybWJUVFZQbVIxdw?oc=5","date":"2026-03-09","type":"earnings","source":"24/7 Wall St.","summary":"Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss - 24/7 Wall St.","headline":"Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss - 24/7 Wall St.","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPRFBOa0FSR2pibVFMaHRVU3k4dFhaUm1MTWJvdjUxR2Vfem9mMWkzQUJZcW5UQkhnNi1PWU5vVkVlSF96UDBiWU42Wl9BN05PZ0NwdkN4TDhQalpwc3RFbXJiUXVrUkU1RFJrbGJnZFA3cGJkSUo1bDhkRVBhMExrN1VOYU4xeFBWZ25Bd0pKTFlOTVZKc3IyMzRIRGxMdGxl?oc=5","date":"2025-12-09","type":"trial","source":"Finviz","summary":"KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Finviz","headline":"KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOVUtfYzYzWFlYczktVmlEVmt5elBqMWREcUNjWm5OYTdYYTBVMHRUbWxOY0xSQnN5SndPMC1vRWhXODRTNzJoa0lTYTVvbWZXbkNlWVprODNSd0hxMldncEgybWVXZFZPN01yQS1UeUs2bG5xMkNWQU1ISldNVmlRVEp5QjdHUVhmSW9OMDdUR1N2c2dTYVNrQVdhNGN3SWZRNUstVlRwRE9JSzRxYVZZRTlfT2drVXhZQzFaXzA5aVphd3puVl9hY2Fja3RDUUMxX0dlMlpBY0RRcU0?oc=5","date":"2025-12-09","type":"regulatory","source":"TechStock²","summary":"Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update - TechStock²","headline":"Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 202","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQcnNZbDZ3TmNMZ1d1RW1sOTlTUGFvQl82NHR6SDJMckcwMjRWUWxva1RCSEVMOTNOdkdmek5jRUNIekhCOVVNQjNRSHpfSHdpbWIyOFlYSDQyU21TajlGbm5xS2lPMXo3LTk0UklVX2M2QnhMVFdVNXlmVEU3Nko3SWNSSVNnTVFtTkJ3ZVZacFFYMHFRa0ZaTDA0SjB1MGM0OUpXYzBvdmc?oc=5","date":"2025-12-08","type":"pipeline","source":"Investor's Business Daily","summary":"Could This Biotech, Up 35%, Have The Next Dupixent? - Investor's Business Daily","headline":"Could This Biotech, Up 35%, Have The Next Dupixent? - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPbHU3T0lfOVdnaVRobWd1U3RhanNtQ0hNUXctMWFrQU5LbTVPUE1zZDBYN21STExISDJZSkZIWk1VYTRYTVVaZkY5LW1IZllWOW9pWHJkLWduTE9XaDJFWHYybnRMVTMxLUxqdG1xay1GaVVUQUR5NlFHeHlJVHA2eFFZY2NzY01tUENFLVFac3ZOSExPV2l0TGxGal9ORGFTOE9JQU53?oc=5","date":"2025-12-08","type":"trial","source":"The Pharma Letter","summary":"Kymera soars on positive Phase Ib Clinical trial of KT-621 - The Pharma Letter","headline":"Kymera soars on positive Phase Ib Clinical trial of KT-621","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxObk5RS2RtVmpEa19mV25rcnlfZnBHSWFYd1FZc3Zua3RndE94NW0tU3UxeWdzMjAxZ08ycnpJdk9aTUc5UWN0dkNNeFlxV2lkalVkeG50ejVqUkdhN2hRTUZmMENyVHVuOXl1NWpPa1JhdXRLTVEzVU5RZ252YXc4X1cyRTMyak1NbG5iNXJkZ21FZDVf?oc=5","date":"2025-12-08","type":"pipeline","source":"Barron's","summary":"Kymera Therapeutics Stock Heads for Record. Investors Are Excited by Its Anti-Inflammatory Drug. - Barron's","headline":"Kymera Therapeutics Stock Heads for Record. Investors Are Excited by Its Anti-Inflammatory Drug. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOczRPeVFySmxqRE5RUmV6c3p3a3h4TFJxYzhLSGlXcjZDSERrQWtQc1BfSUwxbEFlS0wxckIwZmtjaElqcWVYN2JHVFhDZmwxVFFwMVVQQjdxMDJ2SnVxSjYydzhxbm1yWmNJZ1ZuQVE1ZUNzVzZ1NUhzU2pSMmhfMERvbmR2azZsbVdTNWVwRDlJVU05dnI2LVJiRmVBS1h5bnVUOVFXSGlyc3FsTVZmcVk0bVJFRTVxVkk4bjh2QTd2OHBRY0EzTUs1Sl91RWQzWGFNeW9pazI?oc=5","date":"2025-06-25","type":"deal","source":"Reuters","summary":"Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics - Reuters","headline":"Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOb2UtODFiWVB0Tl9jQVdpcVRnWk9lOFpCcldrOGdpOUNhU2NkWlNpbGZuN3NvZHFxTHdwNW9maFR2c2JEUjNlSHhaNm5VY1dUeHFyNkdHdjF0Mmw1aDZuNDBDZndpUW5YUFRFOGlPU1I1QWY0a3FJVUpqc2htWkJrblU5NWx2NERjc2lkTkZpa190TVlBSVdmUi16MjlPYVU3TVlobThNa21qLUs1ZDh2dWJURThjdXNHRHhmc01JNA?oc=5","date":"2025-06-11","type":"pipeline","source":"BioCentury","summary":"Kymera’s STAT6 degrader breaks ahead of competition: BioCentury’s Clinical Report - BioCentury","headline":"Kymera’s STAT6 degrader breaks ahead of competition: BioCentury’s Clinical Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBMOVBtb1ByYmV4MHNLRzcwS09KSy1POXA2dVdCckdhLU9rQU1oak9lOXZmSkgtdHlRUUVnYXlaT2VsZk0ySDROcEs5My1sNy1H?oc=5","date":"2024-03-06","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"KT-333","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Arvinas","Proteostasis Therapeutics","Proteolix"],"therapeuticFocus":["Immunology","Protein Degradation"],"financials":null,"yahoo":{"currentPrice":86.56,"previousClose":85.1,"fiftyTwoWeekHigh":103,"fiftyTwoWeekLow":19.45,"fiftyTwoWeekRange":"19.445 - 103.0","fiftyDayAverage":81.32,"twoHundredDayAverage":63.3,"beta":2.29,"enterpriseValue":6181743616,"forwardPE":-21.6,"priceToBook":4.46,"priceToSales":180.24,"enterpriseToRevenue":157.65,"enterpriseToEbitda":-18.24,"pegRatio":0,"ebitda":-338831008,"ebitdaMargin":0,"freeCashflow":-136041248,"operatingCashflow":-232891008,"totalDebt":82252000,"debtToEquity":5.2,"currentRatio":10.47,"returnOnAssets":-15.9,"returnOnEquity":-25.8,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":21,"targetMeanPrice":119.14,"targetHighPrice":140,"targetLowPrice":91,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.2,"institutionHeldPercent":110.5,"sharesOutstanding":81642394,"floatShares":54436699,"sharesShort":9968655,"shortRatio":12.7,"shortPercentOfFloat":12.2,"epsTrailing":-3.69,"epsForward":-4.01,"revenuePerShare":0.46,"bookValue":19.42,"officers":[{"age":51,"name":"Dr. Bruce L. Booth DPHIL, Ph.D.","title":"Co-Founder & Independent Chairman"},{"age":46,"name":"Dr. Nello  Mainolfi M.D., Ph.D.","title":"Co-Founder, President, CEO & Director"},{"age":null,"name":"Mr. Bruce N. Jacobs CFA","title":"Chief Financial Officer"},{"age":62,"name":"Dr. Jeremy G. Chadwick Ph.D.","title":"Chief Operating Officer"},{"age":60,"name":"Dr. Jared A. Gollob M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Ms. Justine E. Koenigsberg","title":"Vice President of Investor Relations"},{"age":51,"name":"Mr. Brian R. Adams J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":66,"name":"Dr. Neil  Graham M.D., M.P.H., MBBS","title":"Chief Development Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.kymeratx.com","phone":"857 285 5300"}}